HEMIBIO
HEPATIC MICROFLUIDIC BIOREACTOR
| Coordinatore | KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 9˙400˙000 € |
| EC contributo | 4˙700˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-Alternative-Testing |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | coordinator | 785˙300.80 |
| 2 |
VRIJE UNIVERSITEIT BRUSSEL
Organization address
address: PLEINLAAN 2 contact info |
BE (BRUSSEL) | participant | 583˙181.25 |
| 3 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 477˙426.00 |
| 4 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 471˙533.62 |
| 5 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 413˙878.34 |
| 6 |
MEDICYTE GMBH
Organization address
address: Im Neuenheimer Feld 581 contact info |
DE (Heidelberg) | participant | 287˙734.00 |
| 7 |
INTERUNIVERSITAIR MICRO-ELECTRONICA CENTRUM VZW
Organization address
address: Kapeldreef 75 contact info |
BE (LEUVEN) | participant | 283˙237.66 |
| 8 |
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT
Organization address
address: RUE JAQUET DROZ 1 contact info |
CH (NEUCHATEL) | participant | 282˙953.62 |
| 9 |
UNIVERSITETET I TROMSOE
Organization address
address: Hansine Hansens veg 14 contact info |
NO (TROMSO) | participant | 281˙749.56 |
| 10 |
UNIVERSITETET I OSLO
Organization address
address: Problemveien 5-7 contact info |
NO (OSLO) | participant | 279˙561.30 |
| 11 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: CALLE ROSSELLO 149 PUERTA BJS contact info |
ES (BARCELONA) | participant | 276˙801.80 |
| 12 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 188˙873.38 |
| 13 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 87˙768.62 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three cell types to induce and maintain their functional, differentiated state, and (b) optimisation of the matrix, oxygenation conditions, nutrient transport and physiological shear forces. The objectives are (1) to engineer the cellular components incorporated in the bioreactor to enable specific and spatially defined enrichment of the different cells from iPSC progeny, and, by gene editing, to allow non-invasive monitoring of the cellular state (differentiation and damage). (2) Aside from the molecular sensors, an array of electro-chemical sensors will be embedded in the reactors to assess liver-specific function and cellular health under repeated dose toxicity conditions, dynamically and in a high-throughput way. Cells and sensors will be built into (3) bioreactors that will be sequentially upgraded from 2D to 3D microfluidic reactors to ultimately allow full maintenance of mature functional hepatocytes, HSC and HSEC for >28 days. (4) As the ultimate goal is to use the device as a human-based alternative to rodent long-term hepatotoxicity studies, it will be of utmost importance to provide proof of concept that the 3D-devices reveal the hepatotoxicity of prototypical hepatotoxic compounds in vivo (5). “-Omics” and cell functionality studies will provide evidence that liver-like cells are present, exposed and affected by the selected toxic compounds. These ambitious objectives will be achieved by the excellent project team, composed of academic/industrial partners with unique and complementary biology, physiology, toxicology and technical skills from 7 EU Member States.'
Introduzione (Teaser)
Replacing animals in toxicity testing is important for the biotechnology, pharmaceutical and cosmetics industries. There is a need for new human cell models, due to the often poor correlation between animal and human toxicity testing.